DE60040024D1 - Immunologische kontrolle des beta-amyloid gehaltes in vivo - Google Patents
Immunologische kontrolle des beta-amyloid gehaltes in vivoInfo
- Publication number
- DE60040024D1 DE60040024D1 DE60040024T DE60040024T DE60040024D1 DE 60040024 D1 DE60040024 D1 DE 60040024D1 DE 60040024 T DE60040024 T DE 60040024T DE 60040024 T DE60040024 T DE 60040024T DE 60040024 D1 DE60040024 D1 DE 60040024D1
- Authority
- DE
- Germany
- Prior art keywords
- amyloid
- vivo
- beta
- methods
- immunological control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/724—Devices having flexible or movable element
- Y10S977/727—Devices having flexible or movable element formed from biological material
- Y10S977/729—From protein or unit thereof, e.g. enzyme or carboxyl group
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
- Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13940899P | 1999-06-16 | 1999-06-16 | |
PCT/US2000/016551 WO2000077178A1 (en) | 1999-06-16 | 2000-06-15 | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60040024D1 true DE60040024D1 (de) | 2008-10-02 |
Family
ID=22486496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60040024T Expired - Lifetime DE60040024D1 (de) | 1999-06-16 | 2000-06-15 | Immunologische kontrolle des beta-amyloid gehaltes in vivo |
Country Status (12)
Country | Link |
---|---|
US (9) | US6582945B1 (de) |
EP (1) | EP1409654B1 (de) |
JP (1) | JP5249482B2 (de) |
AT (1) | ATE405636T1 (de) |
AU (1) | AU780474B2 (de) |
CA (1) | CA2376693C (de) |
CY (1) | CY1108566T1 (de) |
DE (1) | DE60040024D1 (de) |
DK (1) | DK1409654T3 (de) |
ES (1) | ES2312348T3 (de) |
PT (1) | PT1409654E (de) |
WO (1) | WO2000077178A1 (de) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
TR200202799T3 (tr) * | 2000-02-24 | 2003-03-21 | Washington University St.Louis | AB peptidini sekanslayan insanlaştırılmış antikorlar |
PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
ES2437875T3 (es) | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
DE60229051D1 (de) | 2001-04-30 | 2008-11-06 | Lilly Co Eli | Humanisierte antikörper |
WO2003016466A2 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
US20060073149A1 (en) * | 2001-08-17 | 2006-04-06 | Bales Kelly R | Rapid improvement of cognition in condition related to abeta |
DK1944040T3 (da) | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
CN100488982C (zh) * | 2001-11-02 | 2009-05-20 | 迪尔基因国际有限公司 | 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法 |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CA2483729A1 (en) * | 2002-04-25 | 2003-11-06 | Eli Lilly And Company | Method for treating anxiety and mood disorders in older subjects |
EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
CA2501945A1 (en) * | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
KR20050118669A (ko) * | 2003-02-01 | 2005-12-19 | 뉴랄랩 리미티드 | 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화 |
ATE468886T1 (de) | 2003-02-10 | 2010-06-15 | Applied Molecular Evolution | Abeta-bindende moleküle |
TWI374893B (en) * | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2005014041A2 (en) * | 2003-07-24 | 2005-02-17 | Novartis Ag | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
BRPI0506793A (pt) * | 2004-02-20 | 2007-05-22 | Rinat Neuroscience Corp | métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 |
US20050225165A1 (en) * | 2004-04-13 | 2005-10-13 | Naik Sanjeev M | Brake by-wire control system |
EA016357B1 (ru) * | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Антитела, направленные против бета-амилоидного пептида, и способы их применения |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
PE20061401A1 (es) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
MY148086A (en) * | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
RU2015111675A (ru) * | 2005-12-12 | 2015-08-10 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
RS52004B (en) | 2005-12-12 | 2012-04-30 | F. Hoffmann-La Roche Ag | ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
NL2000464C2 (nl) * | 2006-02-02 | 2007-09-11 | Rinat Neuroscience Corp | Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist. |
US7935342B2 (en) * | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
CA2641672A1 (fr) * | 2006-02-09 | 2007-08-16 | Alain Dibie | Systeme de traitement de lesions sur une bifurcation de vaisseau sanguin |
US8992928B2 (en) | 2006-02-11 | 2015-03-31 | Victor Raso | Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2007133807A2 (en) * | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
KR101605207B1 (ko) * | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
US8497246B2 (en) * | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008079324A1 (en) * | 2006-12-21 | 2008-07-03 | Boston Biomedical Research Institute | Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity |
PT2842967T (pt) * | 2007-01-18 | 2017-01-13 | Lilly Co Eli | Fab beta amilóide peguilado |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
EP2481408A3 (de) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Neue Verwendung von Inhibitoren der Glutaminyl Cyclase |
WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
JP2010523595A (ja) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ(アミノ酸)ターゲッティング部分 |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US8323654B2 (en) * | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
EP2152309B1 (de) * | 2007-05-14 | 2013-07-10 | Medtronic, Inc. | Verfahren und vorrichtung zur neutralisierung von löslichen giftstoffen im gehirn |
CN101820911B (zh) * | 2007-06-12 | 2015-05-06 | Ac免疫有限公司 | β淀粉样蛋白的人源化抗体 |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8974791B2 (en) | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
EP2023143A1 (de) * | 2007-08-06 | 2009-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Immunogene Streptokokkus-Proteine |
EP2238166B1 (de) * | 2007-10-05 | 2013-11-27 | Genentech, Inc. | Verwendung eines anti-amyloid-beta-antikörpers bei augenkrankheiten |
NZ585110A (en) * | 2007-10-05 | 2012-09-28 | Genentech Inc | Method and compositions for diagnosis and treatment of amyloidosis |
RU2542967C2 (ru) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
WO2009111906A1 (zh) * | 2008-03-13 | 2009-09-17 | 天津医科大学 | 用于预防和/或治疗阿尔茨海默病的β片层阻断肽 |
CN101531703B (zh) * | 2008-03-13 | 2013-04-24 | 天津医科大学 | 用于预防和/或治疗阿尔茨海默病的β片层阻断肽 |
EP2149380A1 (de) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Tierärztliche Immuntherapiezusammensetzung für altersbedingte kognitive Dysfunktion |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010108048A2 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
AU2010294214B2 (en) | 2009-09-11 | 2015-05-07 | Vivoryon Therapeutics N.V. | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
SI2485761T1 (sl) | 2009-10-09 | 2019-05-31 | Armagen, Inc. | Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP2560953B1 (de) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Hemmer der glutaminylzyklase |
SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
SI2646470T1 (sl) | 2010-11-30 | 2017-05-31 | F. Hoffmann-La Roche Ag | Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
JP6266529B2 (ja) | 2011-12-02 | 2018-01-24 | アーマジェン・インコーポレイテッドArmagen, Inc. | Cnsにおけるアリールスルファターゼa活性を増加するための方法および組成物 |
KR102115438B1 (ko) | 2012-05-21 | 2020-05-27 | 제넨테크, 인크. | 혈액-뇌 장벽 수송의 안전성을 개선하는 방법 |
CN104520329A (zh) * | 2012-08-29 | 2015-04-15 | 霍夫曼-拉罗奇有限公司 | 血脑屏障穿梭体 |
ES2503516B1 (es) * | 2013-04-03 | 2015-09-09 | Inmunotek, S.L. | Complejo inmunogénico para vacunación y método de obtención |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
DK3313879T3 (da) | 2015-06-24 | 2022-03-14 | Hoffmann La Roche | Anti-transferrinreceptor-antistoffer med tilpasset affinitet |
CN114014936A (zh) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
US20220268789A1 (en) * | 2019-07-05 | 2022-08-25 | Shimadzu Corporation | Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US5900237A (en) * | 1983-11-29 | 1999-05-04 | Igen International, Inc. | Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies |
US5187153A (en) * | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
EP0273696A2 (de) * | 1987-01-02 | 1988-07-06 | Merck & Co. Inc. | Renin-Inhibitoren, in denen Histidin ersetzt ist |
US6702705B1 (en) * | 1988-05-04 | 2004-03-09 | Igen International, Inc. | Prodrugs activated by targeted catalytic proteins |
ZA893284B (en) * | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
US5190865A (en) * | 1988-11-18 | 1993-03-02 | The Regents Of The University Of California | Antibody-enhanced stereospecific hydrolyses |
US6329508B1 (en) * | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
ATE153534T1 (de) * | 1990-04-27 | 1997-06-15 | John Mcmichael | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein |
US5439812A (en) | 1992-04-08 | 1995-08-08 | The Pennsylvania Research Corporation | Antibodies catalyzing deamidation of proteins |
AU679675B2 (en) * | 1992-05-11 | 1997-07-10 | Bayer Corporation | Methods for detecting beta amyloid precursor protein processing enzymes |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5955317A (en) * | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
DE69432629T3 (de) * | 1993-01-25 | 2008-01-17 | Takeda Pharmaceutical Co. Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
JP3822231B2 (ja) * | 1993-04-23 | 2006-09-13 | イゲン,インコーポレーテッド | 一級アミドを加水分解する触媒抗体およびそのような抗体を誘発する方法 |
US6136548A (en) * | 1994-11-22 | 2000-10-24 | Rutgers, The State University Of New Jersey | Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging |
US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
GB2326643B (en) * | 1996-03-26 | 2000-09-27 | Amrad Operations Pty Ltd | Precursors of catalytic antibodies |
US6140091A (en) * | 1997-06-20 | 2000-10-31 | Boston Biomedical Research Institute | Anti-idiotype vaccines to elicit catalytic antibodies |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
IT1293510B1 (it) * | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici per la trasformazione in vivo di profarmaci di corticosteroidi |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6294374B1 (en) * | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
TR200202799T3 (tr) | 2000-02-24 | 2003-03-21 | Washington University St.Louis | AB peptidini sekanslayan insanlaştırılmış antikorlar |
-
2000
- 2000-06-15 ES ES00942851T patent/ES2312348T3/es not_active Expired - Lifetime
- 2000-06-15 EP EP00942851A patent/EP1409654B1/de not_active Expired - Lifetime
- 2000-06-15 DK DK00942851T patent/DK1409654T3/da active
- 2000-06-15 PT PT00942851T patent/PT1409654E/pt unknown
- 2000-06-15 AT AT00942851T patent/ATE405636T1/de active
- 2000-06-15 AU AU57421/00A patent/AU780474B2/en not_active Ceased
- 2000-06-15 DE DE60040024T patent/DE60040024D1/de not_active Expired - Lifetime
- 2000-06-15 WO PCT/US2000/016551 patent/WO2000077178A1/en active IP Right Grant
- 2000-06-15 CA CA2376693A patent/CA2376693C/en not_active Expired - Fee Related
- 2000-06-15 JP JP2001503623A patent/JP5249482B2/ja not_active Expired - Fee Related
- 2000-06-15 US US09/594,366 patent/US6582945B1/en not_active Expired - Lifetime
-
2001
- 2001-11-06 US US09/992,800 patent/US6872554B2/en not_active Expired - Lifetime
- 2001-11-06 US US09/992,994 patent/US20020136718A1/en not_active Abandoned
-
2003
- 2003-03-10 US US10/385,065 patent/US7413884B2/en not_active Expired - Lifetime
-
2005
- 2005-02-23 US US11/063,350 patent/US7906626B2/en not_active Expired - Fee Related
-
2006
- 2006-01-03 US US11/324,500 patent/US20060228371A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/150,455 patent/US20090074748A1/en not_active Abandoned
- 2008-11-14 CY CY20081101312T patent/CY1108566T1/el unknown
-
2013
- 2013-04-11 US US13/860,966 patent/US20140086937A1/en not_active Abandoned
-
2015
- 2015-04-16 US US14/688,449 patent/US20160039915A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5249482B2 (ja) | 2013-07-31 |
CY1108566T1 (el) | 2014-04-09 |
CA2376693C (en) | 2013-09-10 |
US6872554B2 (en) | 2005-03-29 |
AU5742100A (en) | 2001-01-02 |
US20090074748A1 (en) | 2009-03-19 |
PT1409654E (pt) | 2008-11-25 |
US7906626B2 (en) | 2011-03-15 |
EP1409654A4 (de) | 2004-12-29 |
AU780474B2 (en) | 2005-03-24 |
DK1409654T3 (da) | 2008-12-08 |
US20030235897A1 (en) | 2003-12-25 |
US20140086937A1 (en) | 2014-03-27 |
US20050147613A1 (en) | 2005-07-07 |
US20020136718A1 (en) | 2002-09-26 |
CA2376693A1 (en) | 2000-12-21 |
US7413884B2 (en) | 2008-08-19 |
US20160039915A1 (en) | 2016-02-11 |
US6582945B1 (en) | 2003-06-24 |
US20020102261A1 (en) | 2002-08-01 |
ATE405636T1 (de) | 2008-09-15 |
WO2000077178A1 (en) | 2000-12-21 |
ES2312348T3 (es) | 2009-03-01 |
US20060228371A1 (en) | 2006-10-12 |
EP1409654B1 (de) | 2008-08-20 |
EP1409654A1 (de) | 2004-04-21 |
JP2003506321A (ja) | 2003-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60040024D1 (de) | Immunologische kontrolle des beta-amyloid gehaltes in vivo | |
WO2002060955A3 (en) | Modified antibodies and methods of use | |
EP2228389A3 (de) | Antikörper gegen vaskulären Endothelwachstumsfaktor 2 | |
ATE202940T1 (de) | Mittel und methoden zur behandlung von plaque- krankheiten | |
ATE194608T1 (de) | 5-substituierte derivate von mycophenolsäure | |
WO2002083849A3 (en) | Vascular endothelial growth factor 2 | |
DE60042137D1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
DE60045721D1 (de) | Streptococcus pneumoniae Proteine und Impfstoffe | |
DE3685853T2 (de) | Mittel zur behandlung von knochenkrankheiten. | |
PL376964A1 (pl) | Leczenie miażdżycy tętnic przez bierne uodpornienie peptydem | |
EA200401295A1 (ru) | Статиновая терапия для усиления поддержания когнитивной функции | |
ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen | |
DE50000562D1 (de) | Mittel zur behandlung von pigmentierungsstörungen | |
WO2003034069A3 (en) | Tcmp 03 protein for use in cancer therapy | |
UA29106A (uk) | Спосіб лікування вібраційної хвороби |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |